ACMSD and metabolic dysfunction-associated steatotic liver disease: We have previously demonstrated that inhibiting ACMSD can increase NAD+ levels in mouse liver.18 Nonetheless, its therapeutic potential in mouse models that mimic human MASLD/MASH is unexplored.